Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy
نویسندگان
چکیده
منابع مشابه
Nucleoside Reverse Transcriptase Inhibitors
Although the incidence of HIV infection among women is increasing, the proportion of women in clinical trials that evaluate interventions for the treatment of HIV infection and its complications has historically been lower than the proportion of women in the HIV/AIDS patient population. Therefore, most knowledge about the efficacy of antiretroviral drugs and the adverse reactions associated wit...
متن کاملRilpivirine: a new non-nucleoside reverse transcriptase inhibitor
Rilpivirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved for HIV-1 treatmentnaive adult patients in combination with other antiretroviral agents. The recommended dose is a 25 mg tablet once daily taken orally with a meal. Due to cytochrome P450 3A4 enzyme induction or gastric pH increase, rilpivirine cannot be coadministered with a number of other drugs (anti...
متن کاملRilpivirine: a novel non-nucleoside reverse transcriptase inhibitor.
Combination antiretroviral therapy has transformed the prognosis and life expectancy of HIV-1 infected individuals in resource-rich settings. British guidelines currently recommend the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz as part of first-line treatment in therapy-naive HIV-1 infected individuals. However, efavirenz is limited by its low genetic barrier to the develo...
متن کاملHIV Nucleoside Reverse Transcriptase Inhibitors
Currently, 16 antiretroviral drugs are approved for treatment of HIV infection. However, even the best currently available regimens pose challenges with regard to adherence, toxicity, antiviral activity, and resistance. New drug development thus confronts the need for improved convenience and tolerability, reduced toxicity, and improved activity against both wild-type and drug-resistant viruses...
متن کاملNucleoside Reverse Transcriptase Inhibitors (NRTIS)
substantial progress continues to be made in the arena of antiretroviral drug development. prn is again proud to present its annual review of the experimental agents to watch for in the coming months and years. This year’s review is based on a lecture by Dr. Roy M. Gulick, a longtime friend of prn, and no stranger to the antiretroviral development pipeline. To date, twenty-two antiretrovirals h...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacogenomics
سال: 2009
ISSN: 1462-2416,1744-8042
DOI: 10.2217/pgs.09.14